🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT02933229
Starting soon Phase 4

The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study

NCT02933229 · tracked via the Priya Life Science China tracker
Sponsor
Shandong University
Phase
Phase 4
Started
2016-10
Last updated
2016-10-14

Condition(s) studied

Helicobacter Pylorithe Operative Link on Gastric Intestinal MetaplasiaOperative Link on Gastric Intestinal Assessment

Investigational drug(s) / intervention(s)

biopsyH. pylori eradication

biopsy: patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.

H. pylori eradication: H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin. If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.

Study summary

Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with H. pylori infection; * Aged 18-65 years. Exclusion Criteria: * Patients with gastrectomy, acute GI bleeding and advanced gastric cancer; * Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function; * Pregnancy or breastfeeding; * Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Gastroenterology, Qilu Hospital, Shandong University Jinan Shandong

More Shandong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02933229 on ClinicalTrials.gov ↗ ← All trials in China